AU Patent

AU2023390277A1 — Cancer combination therapy using cd24 antibody and pd-1-pd-l1 pathway blocking antibody

Assigned to Immuneonco Biopharmaceuticals Shanghai Inc · Expires 2025-05-29 · 1y expired

What this patent protects

The present application relates to a composition, comprising i) an antibody that specifically binds to CD24 or an antigen-binding moiety thereof, and ii) an antibody capable of blocking PD-1-PD-L1 binding/interaction or an antigen-binding moiety thereof, and use of the compositio…

USPTO Abstract

The present application relates to a composition, comprising i) an antibody that specifically binds to CD24 or an antigen-binding moiety thereof, and ii) an antibody capable of blocking PD-1-PD-L1 binding/interaction or an antigen-binding moiety thereof, and use of the composition in cancer therapy. The present application further relates to a cancer combination therapy using i) the antibody that specifically binds to CD24 or the antigen-binding moiety thereof and ii) the antibody capable of blocking PD-1-PD-L1 binding/interaction or the antigen-binding moiety thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023390277A1
Jurisdiction
AU
Classification
—
Expires
2025-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Immuneonco Biopharmaceuticals Shanghai Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.